Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    Fishfa Biogenics: Renowned Manufacturer, & Exporter of Tacrolimus & Mupirocin API.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Sulbactam

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 118Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Enforcement Report - Week of May 24, 2023
    Enforcement Report - Week of May 24, 2023

    24 May 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-24-2023-89772.pdf

    FDA
    24 May 2023
    Share Share
    Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO
    Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO

    23 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230523005961/en

    BUSINESSWIRE
    23 May 2023
    Share Share
    Pfizer halts 4 antibiotics in India due to production issues
    Pfizer halts 4 antibiotics in India due to production issues

    19 May 2023

    // Joseph Keenan FIERCE PHARMA

    https://www.fiercepharma.com/manufacturing/pfizer-puts-kibosh-4-antibiotics-india-due-manufacturing-issues

    Joseph Keenan FIERCE PHARMA
    19 May 2023
    Share Share
    Results from Phase 3 ATTACK Trial Published in The Lancet Infectious Diseases
    Results from Phase 3 ATTACK Trial Published in The Lancet Infectious Diseases

    11 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230511005905/en

    BUSINESSWIRE
    11 May 2023
    Share Share
    FDA panel backs Innoviva's drug for multidrug-resistant bacterial infections
    FDA panel backs Innoviva's drug for multidrug-resistant bacterial infections

    18 Apr 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-backs-innovivas-drug-multidrug-resistant-bacterial-infections-2023-04-17/

    REUTERS
    18 Apr 2023
    Share Share
    Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA
    Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA

    17 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230417005846/en

    BUSINESSWIRE
    17 Apr 2023
    Share Share